Merck & Co (MRK) Announces the Approval of ENFLONSIA

Merck & Co., Inc. (NYSE:MRK) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 26, Merck & Co., Inc. (NYSE:MRK) announced that the Advisory Committee on Immunization Practices has approved ENFLONSIA for preventing respiratory syncytial virus in infants younger than 8 months. The recommendation is provisional and is pending the final approval of the CDC Director or the Health and Human Services Secretary.

Merck & Co., Inc. (NYSE:MRK) noted that ENFLONSIA is the first and only RSV preventive option administered to infants using the same dose regardless of weight, simplifying dosing logistics. Moreover, earlier this month, the FDA approved ENFLONSIA based on the strong clinical trial data from the Phase 2b/3 CLEVER and Phase 3 SMART trials. The results showed a 60.5% reduction in medically attended RSV lower respiratory infections and an 84.3% reduction in RSV-associated hospitalizations.

Merck & Co (MRK) Announces the Approval of ENFLONSIA

A close-up of a person’s hand holding a bottle of pharmaceuticals.

Merck & Co., Inc. (NYSE:MRK) is a global healthcare company that operates through two main business segments including the Pharmaceuticals and Animal Health Segments. It is known for Keytruda and Gardasil, which are the main sources of the company’s revenue.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.